SynthesisFrontiers in immunology2024

Efficacy and safety of adding immune checkpoint inhibitors to first-line standard therapy for recurrent or advanced cervical cancer: a meta-analysis of phase 3 clinical trials.

Xinmiao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.